Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
May 10 2022 - 4:15PM
Business Wire
In accordance with Articles L.233-8 II of
the French Commercial Code and 223-16 of the General Regulations of
the Autorité des Marchés Financiers (French Financial Markets
Authority)
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN
code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA
Website: www.nanobiotix.com
Date
Number of Shares
Outstanding
Total number of voting
rights
Total voting rights, gross
(1)
Total voting rights, net
(2)
April 30, 2022
34,875,872
36,392,064
36,371,073
(1) The total number of gross (or “theoretical”) voting rights
is used as the basis for calculating threshold crossings. In
accordance with Article 223-11 of the AMF General Regulations, this
number is calculated on the basis of all shares to which voting
rights are attached, including those for which voting rights have
been suspended.
(2) The total number of net (or “exercisable at a Shareholders’
Meeting”) voting rights is calculated without taking into account
shares for which voting rights have been suspended. It is released
in order to ensure that the public is properly informed, in
accordance with the AMF recommendation of July 17, 2007.
***
About NANOBIOTIX: http://www.nanobiotix.com Nanobiotix is
a late-stage clinical biotechnology company pioneering disruptive,
physics-based therapeutic approaches to revolutionize treatment
outcomes for millions of patients; supported by people committed to
making a difference for humanity. The company’s philosophy is
rooted in the concept of pushing past the boundaries of what is
known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris,
France. The company also has subsidiaries in Cambridge,
Massachusetts (United States), France, Spain, and Germany.
Nanobiotix has been listed on the regulated market of Euronext:
Paris since 2012 and on the Nasdaq Global Select Market in New York
City since December 2020.
Nanobiotix is the owner of more than 30 umbrella patents
associated with three (3) nanotechnology platforms with
applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous system.
The company's resources are primarily devoted to the development of
its lead product candidate– NBTXR3—which is the product of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at
www.nanobiotix.com or follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220510006048/en/
Nanobiotix
Nanobiotix Communications Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com
Nanobiotix Investor Relations Kate McNeil SVP, Investor
Relations +1 (609) 678-7388 investors@nanobiotix.com
Media Relations
France – Ulysse Communication Pierre-Louis Germain + 33
(0) 6 64 79 97 51 plgermain@ulysse-communication.com
US – Porter Novelli Caitlin Hunt +1 (781)985-5967
Caitlin.hunt@porternovelli.com
Nanometrics (NASDAQ:NANO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nanometrics (NASDAQ:NANO)
Historical Stock Chart
From Sep 2023 to Sep 2024